

TABLE OF CONTENTS

Abbreviations	3
I. Introduction	4
II. What Are Access to Information Regimes? What Are Trade Secrets? How do they Interact?	8
II.1 What are trade secrets and CBI?	9
Trade secrets, intellectual property, and public policy?	10
II.2 What are access to information regimes in the environmental and health contexts	10
Utilitarian arguments	11
Fairness and justice arguments	12
II.3 The nature of the conflict	12
India	15
South Africa	15
The European Union	15
II.4 Conclusion	16
III. Access to Information in Environmental Treaties	17
III.1 The Aarhus Convention	18
Internal rules for resolving conflict with confidential or other undisclosed information	18
The rule for relating to other international treaties	20
III.2 Convention on Biological Diversity	22
Internal rules for resolving conflict with protection of trade secrets and CBI	22
The rule for relating to other international treaties	23
III.3 The Nagoya Protocol	24
The rule for relating to other international treaties	26
IV. The international human rights framework affecting access to and use of pharmaceutical test data	28
V. Conclusions on Access to Information Regimes in the Environmental and Health arena	35
VI. International Provisions on Protection of Undisclosed Information	37
The internal rules for relating to public disclosure and access to information	38
Rules on the relationship to other regimes	47
VII. General Conclusions and Recommendations	50
VII.1 General conclusions on protection of undisclosed information submitted to the state	51
VII.2 General recommendations on the protection of undisclosed information	51
VII.3 Recommendations for implementation of the Nagoya Protocol.	51
VII.4 Recommendation on disclosure and use of pharmaceutical test data	54